MYOV News and Press, Myovant Sciences Ltd. From 05/06/22

Vinco Ventures (BBIG) +33% on confirming distribution date for planned spin-off of blockchain business Cryptyde. Funko (FNKO) +20% after attracting new investor, striking deal with eBay. Opendoor Technologies (OPEN) +14% on Q1 results. ChemoCentryx (CCXI) +1...

ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION PR Newswire CARY, N.C. and BASEL, Switzerland , May 6, 2022 /PRNewswire/ -- Altavant Sciences , a c...

BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE ®...

ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530 PR Newswire CARY, N.C. , and BASEL, Switzerland , May 2, 2022 /PRNewswire/ -- Altavant Sciences , a clinical-stage biopharm...

ORGOVYX ® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe Myovant expects to secure European commercialization partner ahead of anticipated launches ...

Johnson and Johnson's (NYSE:JNJ) Janssen unit has submitted a marketing authorization application to the European Medicines Agency (EMA) seeking approval of a combination of Zytiga (abiraterone acetate) and Zejula (niraparib) for prostate cancer. The approval Janssen is seeking is for th...

The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis. Irrespective of the FDA decision, I strongly believe that relugolix will ultimately gain approval for endometriosis (perhaps in either Q3 or Q4 this year). ...

BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2021, ended March 31, 2022. The webcast and c...

FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors...

CAMBRIDGE, Mass. and BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today plans to develop a Good Manufacturing Practice (GMP)-compliant regenerative medicine manuf...